UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended MARCH 31, 1996
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File No. 33-17922-C
IMMUNE RESPONSE, INC.
---------------------
(Exact Name of Registrant as Specified in its Charter)
Colorado 84-0950197
- -------- ----------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
7315 East Peakview Avenue
Englewood, Colorado 80111
- ------------------------- -----
(Address of principal executive offices) (Zip code)
(303) 796-8940
--------------
(Registrant's telephone number including area code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months, and (2) has been subject to such filing requirements
for the past 90 days. Yes [ X ] No [ ]
Number of shares of common stock outstanding at May 3, 1996: 294,970,000
<PAGE>
IMMUNE RESPONSE, INC.
Part 1. FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
The accompanying interim unaudited condensed financial statements have been
prepared in accordance with the instructions to Form 10-QSB and do not include
all the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring adjustments) considered necessary
for a fair presentation have been included, and the disclosures are adequate to
make the information presented not misleading. Operating results for the three
months ended March 31, 1996 are not necessarily indicative of the results that
may be expected for the year ended December 31, 1996. These statements should be
read in conjunction with the financial statements and notes thereto included in
the Annual 10-KSB Report (filed with the Securities and Exchange Commission) for
the year ended December 31, 1995.
F-1
<PAGE>
IMMUNE RESPONSE, INC.
(A Development Stage Company)
Balance Sheet
March 31, 1996
(Unaudited)
<TABLE>
<S> <C>
ASSETS
Current assets
Cash and cash equivalents .................................. $ 38,852
Note receivable, net of allowance
for doubtful accounts of $6,338 ......................... 126,544
Interest receivable, net of allowance
for doubtful accounts of $1,537 ....................... 1,893
---------
167,289
Other assets
Investment in MacGregor (cost of $3,907) ................... 17,868
---------
$ 185,157
=========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Notes payable - related entity ............................. $ 76,100
Accounts payable - related entity .......................... 2,609
Accrued salary to officer .................................. 11,250
Accounts payable - others .................................. 23,925
Accounts payable - directors ............................... 4,800
Interest payable - related entity .......................... 37,834
---------
156,518
Stockholders' equity
Common stock, $.0001 par value; 950,000,000
shares authorized; 312,470,000 shares
issued; 294,970,000 shares outstanding .................. 31,247
Additional paid-in capital ................................. 877,906
Unrealized gain on available for sale securities ........... 13,910
Deficit accumulated during the
development stage ....................................... (894,424)
Less: treasury stock, at cost
(17,500,000 shares) ..................................... --
---------
28,639
---------
$ 185,157
=========
</TABLE>
F-2
<PAGE>
IMMUNE RESPONSE, INC.
(A Development Stage Company)
Statements of Operations
(Unaudited)
<TABLE>
<CAPTION>
For the
periom from
inception
For the three months (May 14,
ended March 31, 1984) to
1996 1995 March 31, 1996
---- ---- --------------
<S> <C> <C> <C>
Revenue
Interest income ................... $ 4,101 $ 317 $ 115,602
Laboratory test income ............ 50,187
Revenue from sale of marketing
rights to related entity ...... 7,004
Miscellaneous income .............. 1,897
Gain on sale of stock ............. 71,464 192,190
Debt forgiveness income ........... 35,147
------------- ------------- -------------
75,565 317 402,027
Expenses
Write-off of deferred warrant
registration costs ............ 29,422
Loss on sale of laboratory ........ 74,710
Realized loss on investment ....... 178,668
Laboratory supplies ............... 55,244
Consulting fees to related entities 37,500
Interest .......................... 2,131 3,948 130,698
Abandoned license agreement costs . 50,000
Research and development .......... 28,680
Rent .............................. 79,232
Services for stock ................ 7,597
Salary ............................ 275,287
Depreciation and amortization ..... 34,848
Bad debt expense .................. 158 158 7,876
General and administrative ........ 10,457 1,285 306,778
------------- ------------- -------------
12,746 5,391 1,296,451
------------- ------------- -------------
Net income (loss) ............. $ 62,819 $ (5,074) $ (894,424)
============= ============= =============
Net income (loss) per
common share .................. $ (--) $ (--) $ (.004)
============= ============= =============
Weighted average number of
common shares ..................... 294,970,000 294,970,000 242,696,935
============= ============= =============
</TABLE>
F-3
<PAGE>
IMMUNE RESPONSE, INC.
(A Development Stage Company)
Statements of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
For the
period from
inception
For the three months (May 14,
ended March 31, 1984) to
1996 1995 March 31, 1996
---- ---- --------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income (loss) .................... $ 62,819 $ (5,074) $ (894,424)
Adjustments to reconcile net income
(loss) to net cash provided
by operating activities:
Depreciation ....................... 34,848
Abandoned license agreement costs .. 50,000
Services for stock ................. 7,597
Realized net gain on investments ... (71,464) (12,647)
Write-off of deferred warrant
registration costs ............... 29,422
Changes in assets and liabilities:
(Increase) decrease in notes
receivable ...................... (120,206) 158 (407,308)
Decrease (increase) in interest
receivable ...................... (514) (317) (3,272)
Increase in accounts payable
to related entity ................ 68 25 2,609
(Decrease) in accrued legal expenses
payable to former director ....... (52,062)
(Decrease) increase in accounts
payable to directors ............ (3,600) 70 4,800
Increase-accrued salary to officer . 11,250
Increase in interest payable to
related entity .................. 2,131 3,947 37,834
Increase in accounts payable
to others ....................... 1,815 1,199 23,925
----------- ----------- -----------
Net cash provided (used) by
operating activities ............ (181,014) 8 (1,115,605)
----------- ----------- -----------
Cash flows from investing activities:
Proceeds from sale of
investment in MacGregor ............ 89,504 298,071
Purchase of certificate of deposit ... (75,278)
Redemption of certificates of deposit 75,278
Capital expenditures ................. (92,094)
Disposal of laboratory assets ........ 57,246
Purchase of license agreement ........ (50,000)
Acquisition of investment -
related entity .................. (7,000)
----------- ----------- -----------
Net cash used in investing
activities ...................... 89,504 -- 206,223
----------- ----------- -----------
</TABLE>
(Continued)
F-4
<PAGE>
IMMUNE RESPONSE, INC.
(A Development Stage Company)
Statements of Cash Flows (page 2)
(Unaudited)
<TABLE>
<CAPTION>
For the
period from
inception
For the three months (May 14,
ended March 31, 1984) to
1996 1995 March 31, 1996
---- ---- --------------
<S> <C> <C> <C>
Cash flows from financing activities:
Proceeds from issuance of note
payable to bank .................... $ $ $ 50,000
Proceeds from issuance of notes
payable to related entities
and others ......................... 144,964
Payments to retire notes payable
to bank ............................ (50,000)
Payments to retire notes payable
to others .......................... (68,864)
(Increase) in deferred warrant
registration costs ................. (29,422)
Proceeds from issuance of common
stock .............................. 901,556
----------- ----------- -----------
Net cash provided (used) by
financing activities ............ 948,234
----------- ----------- -----------
Net increase (decrease) in cash
and cash equivalents ................. (91,510) 8 38,852
Cash and cash equivalents at
beginning of period .................. 130,362 11
----------- ----------- -----------
Cash and cash equivalents at
end of period ........................ $ 38,852 $ 19 $ 38,852
=========== =========== ===========
Supplemental cash flow information:
Interest received .................... $ $ $ 74,587
=========== =========== ===========
Interest paid ........................ $ $ $ 54,910
=========== =========== ===========
Non-cash financing activities:
Common stock issued for services ..... $ $ $ 7,605
=========== =========== ===========
Investment in common stock of
related entity received in
exchange for marketing rights ...... $ $ $ 7,000
=========== =========== ===========
Exchange of note receivable for
investment in SAC .................. $ $ $ 281,506
=========== =========== ===========
</TABLE>
F-5
<PAGE>
IMMUNE RESPONSE, INC.
Item 2: Management's Discussion and Analysis of Financial Condition
and Results of Operations.
LIQUIDITY, CAPITAL RESOURCES AND RESULTS OF OPERATIONS.
The Company's cash and cash equivalents showed a decrease of $91,510 from
December 31, 1995 to March 31, 1996. The Company's net income for the three
months ended March 31, 1996 of $62,819 was unusual compared to the net loss for
the corresponding period of the prior year of $5,074. This was due to
recognizing a realized gain of $71,464 on sales of the Company's investment in
common stock of MacGregor Sports & Fitness, Inc. $27,500 of the Company's shares
of MacGregor were sold in the open market during the first quarter of 1996 and
the related proceeds were used to retire debts and pay operating expenses. In
addition, the Company advanced $125,000 pursuant to a merger agreement which was
subsequently terminated, which funds have been repaid as of the filing of this
report. This caused the increase in notes and interest receivable compared to a
year ago.
PART II. OTHER INFORMATION
Item 1: Legal Proceedings
None
Item 2: Changes in Securities
None
Item 3: Defaults upon Senior Securities
None
Item 4: Submission of Matters to a Vote of Security Holders
None
Item 5: Other Information
None
Item 6: Exhibits and Reports on Form 8-K
(a) No exhibits in addition to those previously filed or
contained above in this report are required.
(b) During the quarter ended March 31, 1996, the Company
filed no reports on Form 8-K.
F-6
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IMMUNE RESPONSE, INC.
(Registrant)
By: /S/ JOSEPH W. HOVORKA
--------------------------------
Joseph W. Hovorka, President and
Chief Financial Officer
Date: May 14, 1996
F-7
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements contained in the Registrant's Quarterly Report on
Form 10-QSB for the quarter ended March 31, 1996 and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> MAR-31-1996
<CASH> 38,852
<SECURITIES> 0
<RECEIVABLES> 136,312
<ALLOWANCES> 7,875
<INVENTORY> 0
<CURRENT-ASSETS> 167,289
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 185,157
<CURRENT-LIABILITIES> 156,518
<BONDS> 0
0
0
<COMMON> 31,247
<OTHER-SE> (2,608)
<TOTAL-LIABILITY-AND-EQUITY> 185,157
<SALES> 0
<TOTAL-REVENUES> 75,565
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 10,457
<LOSS-PROVISION> 158
<INTEREST-EXPENSE> 2,131
<INCOME-PRETAX> 62,819
<INCOME-TAX> 0
<INCOME-CONTINUING> 62,819
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 62,819
<EPS-PRIMARY> 0
<EPS-DILUTED> 0
</TABLE>
